Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-gamma-glutamyl-S-(naphthalen-1-ylmethyl)-L-cysteinylglycine is a synthetic tripeptide and an oligopeptide derivative of glutathione, in which the cysteine residue is S-substituted with a naphthalenemethyl group. It belongs to the class of organic compounds known as oligopeptides, specifically gamma-glutamyl peptides. This compound is sometimes referred to as a "glutathione conjugate" due to its structural similarity to glutathione and its role as a model substrate for studying glutathione S-transferase-mediated biotransformation. There are no approved therapeutic indications or clinical uses reported for this molecule; it is primarily used in biochemical research settings[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-gamma-glutamyl-S-(naphthalen-1-ylmethyl)-L-cysteinylglycine.